menu search

LBPS / 4D pharma says phase II IBS results published in scientific journal

4D pharma says phase II IBS results published in scientific journal
4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific publication. The article in Alimentary Pharmacology & Therapeutics took a deeper dive into the already revealed finding that the drug has an impact on the symptoms of the two separate IBS cohorts – those with constipation and those with diarrhoea. Read More
Posted: Nov 16 2022, 02:47
Author Name: Proactive Investors
Views: 103197

LBPS News  

4D pharma says phase II IBS results published in scientific journal

By Proactive Investors
November 16, 2022

4D pharma says phase II IBS results published in scientific journal

4D pharma PLC said results from a phase II evaluation of its key irritable bowel treatment LBP Blautix have appeared in a peer-reviewed scientific pub more_horizontal

4D Pharma outlines phase II plans for promising cancer drug candidate

By Proactive Investors
May 27, 2022

4D Pharma outlines phase II plans for promising cancer drug candidate

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) will deliver what's called a ‘trial in progress' poster at a world-leading cancer conference outlining the pla more_horizontal

4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate

By Proactive Investors
May 17, 2022

4D pharma conference poster underlines safety and potential efficacy of asthma drug candidate

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it will present an update from the phase I/II trial of its putative asthma treatment at an industry confere more_horizontal

4D Pharma has a busy year ahead after a successful 12 months of clinical research

By Proactive Investors
April 1, 2022

4D Pharma has a busy year ahead after a successful 12 months of clinical research

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has some significant milestones upcoming this year after a successful 12 months of developing assets that target more_horizontal

4D Pharma PLC soars after meeting endpoint early

By Proactive Investors
March 23, 2022

4D Pharma PLC soars after meeting endpoint early

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) jumped 27% in London trading after the company hit its primary efficacy target in a phase I/II trail of one of i more_horizontal

4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma

By Benzinga
March 23, 2022

4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell Carcinoma

4D pharma plc (NASDAQ: LBPS) has announced interim results from Phase 1/2 study evaluating the combination of MRx0518 and Merck & Co Inc's (NYSE: more_horizontal

4D pharma sees early success as phase I/II cancer trial hits its efficacy target early

By Proactive Investors
March 23, 2022

4D pharma sees early success as phase I/II cancer trial hits its efficacy target early

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) said it had hit its primary efficacy target in a phase I/II trial of one of its lead assets in kidney cancer. MR more_horizontal

4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidates

By Proactive Investors
February 22, 2022

4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidates

4D pharma PLC (AIM:DDDD, NASDAQ:LBPS) has received the green light for a first-in-human trial of its Parkinson's disease candidates in the US. This is more_horizontal


Search within

Pages Search Results: